Abstract: Objective We conducts a real-world study to investigate the efficacy of combination of sofebuvir (SOF) and daclatasvir (DCV) in the treatment of patients with chronic hepatitis C (CHC). Methods A total of 43 patients with CHC were recruited in this study between September 2015 and September 2017, and all patients were treated with combination of SOF and DCV for 12 weeks. The patients were followed-up for 12 to 48 weeks. Results All the 43 patients completed the 12 week regimen and 12 week followed-up. 23 out of the 43 patients completed 24 week and 18 of them completed 48 week treatment-free followed-up. Serum HCV RNA loss at week 2, 4 and 12 were 77.0% (33/43), 93.0% (40/43), and 100.0% (43/43), respectively, and the SVR12 was 100%; serum HCV RNA kept negative in 23 patients 24 weeks, and in 18 patients 48 weeks after discontinuation of the treatment; serum ALT were (28.3±14.4)U /L, (25.4±12.9)U /L,(22.5±9.4)U /L and (21.8±8.6) U /L at the end of week 2, 4, 12 treatment and at the end of 12 week followed-up, respectively, all significantly lower than(66.0±46.1)U /L at presentation (P <0.01) and serum AST levels were(25.4±10.4)U /L, (24.7±9.6)U /L,(22.8±7.7)U /L and (22.3±6.5)U /L, respectively, also all significantly lower than (51.1±31.7)U /L before treatment (P <0.01); at baseline, estimated glomerular filtration rate (eGFR) was less than 90 ml·min^-1·1.73 m² in 8 patients, a certain declines to 60.76 ml·min^-1·1.73 m² were observed during the anti-viral treatment and all returned to pre-treatment levels after withdrawal of the treatment; there was no dose adjustment during the regimen; the common side effects were insomnia (n=3), nausea(n=2),fatigue(n=1), headache(n=1) and alopecia(n=1), and all the phenomena occurred in the early stage of the treatment and relieved without special treatment. Conclusion The application of combination SOF and DCV in the treatment of patients with CHC might get a short-term satisfactory efficacy, which needs long-term observation.

Key words: Hepatitis C, Sofosbuvi, Daclatasvir, Real-world study, Efficacy